Related Experiment Videos
COX-2 selective NSAIDs and advancing legal issues in palliative care
1School of Medicine, Pain Management Center, University of Utah Health Sciences Center, Salt Lake City, UT 84108, USA. fine@aros.net
Abstract:
The role of the cycloxygenase-2 selective NSAIDs in palliative care has not been studied, per se, but the improved adverse gastrointestinal and platelet effect profiles of these newer agents over nonselective NSAIDs offers potential advantages in patients with advanced disease. These issues are discussed. The need for greater emphasis on scientific and evidence-based approaches to palliative care is great and generally recognized in the clinical and scientific communities. Recent legal opinions about aggressive care of patients approaching end of life has increased this need. The clinical and ethical implications of these decisions are discussed.
Insights
Cyclooxygenase-2 selective NSAIDs may offer advantages in palliative care due to better gastrointestinal and platelet safety profiles compared to nonselective NSAIDs. Evidence-based approaches are crucial for end-of-life care decisions.
Area of Science:
- Palliative Care
- Pharmacology
- Pain Management
Background:
- The role of cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs) in palliative care remains understudied.
- Nonselective NSAIDs have known gastrointestinal and platelet-related adverse effects.
- There is a recognized need for increased scientific and evidence-based approaches in palliative care.
Purpose of the Study:
- To discuss the potential advantages of COX-2 selective NSAIDs in palliative care.
- To explore the clinical and ethical implications of end-of-life care decisions.
Main Methods:
- Literature review and discussion of existing data on NSAID safety profiles.
- Analysis of the implications of recent legal opinions on aggressive end-of-life care.
Main Results:
- COX-2 selective NSAIDs present a potentially improved safety profile regarding gastrointestinal and platelet effects compared to nonselective NSAIDs.
- These agents may offer benefits for patients with advanced diseases in palliative care settings.
Conclusions:
- COX-2 selective NSAIDs warrant consideration in palliative care due to their improved adverse effect profiles.
- Strengthening evidence-based practices and addressing clinical-ethical dilemmas are essential in end-of-life care.